Intra-Cellular Therapies v. Aurobindo Pharma: Lumateperone ANDA Dispute Settled by Consent Judgment
Intra-Cellular Therapies filed suit in the District of New Jersey against Aurobindo Pharma asserting 21 U.S. patents protecting lumateperone capsules 42 mg (Caplyta). The parties resolved the dispute through a negotiated settlement and consent judgment in 303 days, with Aurobindo enjoined from infringing the licensed patent portfolio absent specific authorisation.
A 21-patent lumateperone fortress holds: ANDA challenger enjoined
On March 27, 2024, Intra-Cellular Therapies, Inc. (ITCI) filed this Hatch-Waxman infringement action in the U.S. District Court for the District of New Jersey against Aurobindo Pharma, Ltd. and Aurobindo Pharma USA, Inc., asserting 21 U.S. patents covering lumateperone 42 mg capsules — marketed as Caplyta for schizophrenia and bipolar depression. Aurobindo’s filing of Abbreviated New Drug Application No. 218938 with Paragraph IV certifications triggered the statutory 30-month stay and this litigation.
The case concluded on January 24, 2025, via a stipulated consent judgment entered by the court. Under the settlement, Aurobindo is enjoined from infringing any of the 21 Licensed Patents by making, using, selling, or importing its ANDA product without specific authorisation from ITCI under the Settlement Agreement. Notably, the consent judgment preserves Aurobindo’s ability to maintain its Paragraph IV certifications and does not prevent the FDA from granting final approval to ANDA No. 218938 — a structure consistent with a negotiated entry date arrangement.
At 303 days from filing to closure, the resolution is relatively swift for a multi-patent ANDA dispute of this complexity. The absence of any costs or fees award to either party, combined with the preserved FDA approval pathway, suggests the parties reached a commercial licensing arrangement — the precise terms of which remain confidential. What the public record does not reveal is any authorised entry date for Aurobindo’s lumateperone generic, leaving the market exclusivity timeline opaque to third parties.
Filing to Consent Judgment in 303 days
303 days — faster than the median Hatch-Waxman ANDA trial in D.N.J.
Consent judgment and injunction: what the resolution means for both parties
Consent judgment is a court-enforceable settlement, not a merits ruling
A consent judgment combines the finality of a court order with the flexibility of a negotiated agreement. The District Court retains jurisdiction to enforce compliance, meaning any breach by Aurobindo can be treated as contempt rather than requiring a new lawsuit. All claims were dismissed without prejudice — preserving the theoretical right to refile, though that right is practically constrained by the Settlement Agreement’s terms.
Hatch-Waxman consent judgmentITCI secures injunction across all 21 patents without trial risk
ITCI avoided the cost and uncertainty of litigating 21 patents to judgment while obtaining a binding injunction that prevents Aurobindo from launching its lumateperone generic absent authorisation. The preservation of FDA approval rights for ANDA No. 218938 strongly suggests a royalty-bearing licence or defined entry date is embedded in the confidential Settlement Agreement, giving ITCI commercial control over generic entry timing.
Injunction + confidential licenceAurobindo retains ANDA and Paragraph IV certifications — entry date unknown
Aurobindo did not invalidate or design around the ITCI patent estate at this stage. However, the consent judgment expressly preserves ANDA No. 218938 and Aurobindo’s Paragraph IV certifications, indicating the parties negotiated a path to eventual market entry rather than a permanent bar. The specific authorised entry date — if any — is shielded within the confidential Settlement Agreement and is not ascertainable from the public court record.
ANDA preserved; entry date confidential21-patent moat reinforced: high barrier for any remaining ANDA filers
Lumateperone’s 21-patent portfolio — spanning formulation, method of use, and reissued patents — presents a formidable challenge for any subsequent ANDA challenger. This settlement signals that ITCI is prepared to litigate aggressively and negotiate strategically to defend Caplyta’s exclusivity. Competing generic manufacturers holding or contemplating Paragraph IV certifications should treat this consent judgment as a signal that ITCI will enforce its full portfolio and has demonstrated capacity to resolve disputes on favourable terms.
Strong exclusivity signal for CNS genericsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Intra-cellular Therapies, Inc. | Company | CNS pharmaceutical company — holder of 21 U.S. patents covering lumateperone (Caplyta)Search in Eureka ↗ |
| Defendant | Aurobindo Pharma, Ltd. | Company | Generic pharmaceutical manufacturer and U.S. subsidiary that filed ANDA No. 218938 for lumateperone 42 mg capsules.Search in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Katelyn O’Reilly | Attorney | Counsel for Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Lauren Ruth Malakoff | Attorney | Counsel for Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’Reilly Falanga LLP | Law Firm | Representing Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Defendant counsel | Alan S. Golub | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant counsel | Dennies Varughese | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | Fein, Such, Kahn & Shepard, PC | Law Firm | Representing Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | Sterne Kessler Goldstein & Fox | Law Firm | Representing Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment is notable for its dual structure: it functions simultaneously as a binding court injunction and a contractual settlement. The express retention of district court jurisdiction to enforce the Settlement Agreement — not merely the judgment — gives ITCI a direct contempt remedy if Aurobindo launches without authorisation. The dismissal of all claims ‘without prejudice and without costs’ is standard in negotiated ANDA settlements and does not reflect a merits finding on validity or infringement of any of the 21 asserted patents.
US8,648,077 and 20 licensed patents — lumateperone formulation and therapeutic use
The 21 Licensed Patents collectively protect the active pharmaceutical ingredient lumateperone (ITI-007), a serotonin-dopamine activity modulator approved by the FDA as Caplyta for schizophrenia and bipolar I/II depression. The portfolio spans multiple layers of protection: core composition-of-matter claims (US8,648,077, US9,199,995), method-of-treatment claims across multiple indications, formulation and dosage form patents, and two reissued patents (RE48,825, RE48,839) reflecting post-grant claim refinement. The earliest priority dates trace to the mid-2000s, with continuation filings extending exclusivity well into the 2040s.
From a competitive standpoint, this portfolio architecture — combining composition, method, formulation, and reissued claims — is designed to create overlapping layers of protection that make any single invalidity challenge insufficient to clear a path to market. For generic pharmaceutical companies, the reissued patents are particularly significant: post-grant claim amendments can address prior art raised in ANDA proceedings, narrowing the invalidity arguments available to challengers. Any company evaluating a lumateperone ANDA filing should assess not only the granted claims but the prosecution history of the reissued patents and the breadth of the continuation families.
Should your team run an FTO analysis against the lumateperone patent estate?
Any generic pharmaceutical company holding or considering an ANDA filing for lumateperone 42 mg capsules — or any formulation of lumateperone — faces exposure across 21 issued patents plus any pending continuations. R&D teams developing atypical antipsychotics with similar receptor binding profiles should also assess whether method-of-treatment claims extend to comparable CNS indications. The consent judgment in this case confirms ITCI’s willingness to enforce aggressively and litigate in D.N.J., where it has established local counsel relationships.
PatSnap Eureka’s FTO Search Agent can map your product’s claim exposure across the full lumateperone patent family — including reissued patents, continuations, and international equivalents — and identify prosecution history estoppel that may limit claim scope. Use Eureka to generate a freedom-to-operate landscape, monitor new continuation filings by ITCI, and set alerts for any ANDA approval milestones that may signal a licensed entry window opening.
Run a freedom-to-operate analysis on US10464938 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA patent cases in D.N.J.: CNS & pharmaceutical
Explore comparable Hatch-Waxman infringement actions in the District of New Jersey involving CNS pharmaceutical patents and ANDA-triggered multi-patent disputes.
What this case signals for the CNS pharmaceutical IP landscape
A 21-patent ANDA settlement in under a year sets a clear enforcement posture for lumateperone and the broader atypical antipsychotic space.
Portfolio breadth deters ANDA challengers from pursuing full patent trials
When a brand holder asserts 20+ patents spanning formulation, dosing method, and reissued claims, the cost and risk calculus for generic challengers shifts sharply toward settlement. Aurobindo’s rapid resolution — without any published invalidity finding — illustrates how a deep patent thicket functions as a commercial deterrent even before substantive litigation begins.
Preserved FDA pathway in consent judgments: read the fine print
The explicit carve-out allowing FDA to grant final approval to Aurobindo’s ANDA is a hallmark of a negotiated entry-date licence, not a complete block. IP professionals monitoring Caplyta’s exclusivity should watch for FDA tentative or final approval of ANDA No. 218938 as a proxy signal for when any licensed entry window may open.
Intra-cellular v Aurobindo — key questions answered
ITCI asserted 21 U.S. patents designated as ‘Licensed Patents’ in the consent judgment, including US8,648,077, US9,168,258, US9,199,995, US9,616,061, US9,956,227, US10,117,867, US10,464,938, US10,695,345, US10,960,009, US11,026,951, US11,052,084, US11,690,842, US11,753,419, US11,806,348, USRE48,825, USRE48,839, US11,980,617, US12,070,459, US12,090,155, US12,122,792, and US12,128,043, all covering lumateperone 42 mg capsules.
The case was resolved by a consent judgment entered January 24, 2025, approximately 303 days after filing. Aurobindo was enjoined from infringing the 21 Licensed Patents without ITCI’s authorisation. All claims were dismissed without prejudice and without costs. The confidential Settlement Agreement governs any authorised entry conditions for Aurobindo’s ANDA product.
Yes. The consent judgment explicitly states that nothing in the order prevents Aurobindo from maintaining its Paragraph IV certifications or prevents the FDA from granting final approval to ANDA No. 218938. This carve-out is consistent with a negotiated licence structure where Aurobindo may launch at a future authorised date specified in the confidential Settlement Agreement.
Reissued patents indicate ITCI sought and obtained corrected or broadened claim scope after initial grant. For ANDA challengers, this is significant because reissued claims may be harder to invalidate using prior art that was already considered during reissue prosecution. Any FTO or IPR strategy for lumateperone must separately analyse the reissued patent claims and their prosecution history, as the standard invalidity arguments available against original patents may be narrowed.
In this consent judgment, ‘dismissed without prejudice’ means the formal patent infringement claims are terminated without a merits finding on validity or infringement. Theoretically, claims could be refiled, but in practice the Settlement Agreement’s terms govern the parties’ ongoing relationship. The dismissal without prejudice does not reflect any court determination that ITCI’s patents are valid or invalid, or that Aurobindo’s ANDA product does or does not infringe.
PatSnap Eureka searches patents and litigation data to answer instantly.